These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25628464)

  • 41. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging.
    Davison AS; Strittmatter N; Sutherland H; Hughes AT; Hughes J; Bou-Gharios G; Milan AM; Goodwin RJA; Ranganath LR; Gallagher JA
    Metabolomics; 2019 Apr; 15(5):68. PubMed ID: 31037385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homogentisic Acid-Based Whole-Cell Biosensor for Detection of Alkaptonuria Disease.
    Dhyani R; Shankar K; Bhatt A; Jain S; Hussain A; Navani NK
    Anal Chem; 2021 Mar; 93(10):4521-4527. PubMed ID: 33655752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis of alcaptonuria: rapid analysis of homogentisic acid by HPLC.
    Bory C; Boulieu R; Chantin C; Mathieu M
    Clin Chim Acta; 1990 Jul; 189(1):7-11. PubMed ID: 2383921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
    Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
    JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy.
    Wolff JA; Barshop B; Nyhan WL; Leslie J; Seegmiller JE; Gruber H; Garst M; Winter S; Michals K; Matalon R
    Pediatr Res; 1989 Aug; 26(2):140-4. PubMed ID: 2771520
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
    Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adequacy of nitisinone for the management of alkaptonuria.
    Abbas K; Basit J; Rehman MEU
    Ann Med Surg (Lond); 2022 Aug; 80():104340. PubMed ID: 36045846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Phenylalanine- and Tyrosine-Restricted Diet in Alkaptonuria Patients on Nitisinone Treatment: Case Series and Review of Literature.
    Teke Kisa P; Eroglu Erkmen S; Bahceci H; Arslan Gulten Z; Aydogan A; Karalar Pekuz OK; Yuce Inel T; Ozturk T; Uysal S; Arslan N
    Ann Nutr Metab; 2022; 78(1):48-60. PubMed ID: 34736252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Discovery of the Mode of Action of Nitisinone.
    Lock EA
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Alkaptonuria detected during knee arthroplasty treatment].
    Paaskesen CK; Hofbauer C
    Ugeskr Laeger; 2020 Sep; 182(37):. PubMed ID: 33000720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute fatal metabolic complications in alkaptonuria.
    Davison AS; Milan AM; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2016 Mar; 39(2):203-10. PubMed ID: 26596578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
    Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
    Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alkaptonuric Ochronosis.
    Singh O; Muthukrishna Pandian R; Sudhakar Kekre N
    Urology; 2017 Feb; 100():e3-e4. PubMed ID: 27816602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.
    Cox TF; Ranganath L
    J Inherit Metab Dis; 2011 Dec; 34(6):1153-62. PubMed ID: 21744089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.
    Gertsman I; Barshop BA; Panyard-Davis J; Gangoiti JA; Nyhan WL
    JIMD Rep; 2015; 24():13-20. PubMed ID: 25665838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in management of alkaptonuria (invited review; best practice article).
    Ranganath LR; Jarvis JC; Gallagher JA
    J Clin Pathol; 2013 May; 66(5):367-73. PubMed ID: 23486607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.